

AMENDMENTS TO THE CLAIMS

1. - 23. (Canceled)

24. (Currently amended) A pharmaceutical formulation comprising 9-[*R*-2-[[*(S)*-[[*(S)*-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically ~~functional-derivative~~ salt thereof and (2*R*, 5*S*, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1*H*)-pyrimidin-2-one (emtricitabine) or a physiologically ~~functional-derivative~~ salt thereof.

25. (Original) The pharmaceutical formulation according to claim 24 further comprising one or more pharmaceutically acceptable carriers or excipients.

26. (Currently amended) The pharmaceutical formulation according to claim 25 wherein the pharmaceutically acceptable carriers or excipients are selected from pregelatinized starch, croscarmellose sodium, povidone, lactose monohydrate, microcrystalline cellulose, and magnesium stearate; , and combinations thereof.

27. (Currently amended) The pharmaceutical formulation according to claim 24 wherein GS-7340 or a physiologically ~~functional-derivative~~ salt thereof and emtricitabine or a physiologically ~~functional-derivative~~ salt thereof are present in a ratio of 1:50 to 50:1 by weight.

28. (Currently amended) The pharmaceutical formulation according to claim 24 wherein GS-7340 or a physiologically ~~functional-derivative~~ salt thereof and emtricitabine or a physiologically ~~functional-derivative~~ salt thereof are present in a ratio of 1:10 to 10:1 by weight.

29. (Original) The pharmaceutical formulation according to claim 24 in unit dosage form.

30. (Currently amended) The pharmaceutical formulation according to claim 29 wherein GS-7340 or a physiologically ~~functional-derivative~~ salt thereof and emtricitabine or a physiologically ~~functional-derivative~~ salt thereof are each and individually present in an amount from 100 mg to 1000 mg per unit dosage form.

31. (Original) The pharmaceutical formulation according to claim 24 comprising GS-7340 and emtricitabine.

32. (Original) The pharmaceutical formulation according to claim 31 comprising about 150 mg of GS-7340 and about 200 mg of emtricitabine.

33. (Original) The pharmaceutical formulation according to claim 24 suitable for oral administration.

34. (Original) The pharmaceutical formulation according to claim 30 in the form of a tablet or capsule.

35. (Original) The pharmaceutical formulation according to claim 30 suitable for administration once per day to an infected human.

36. (Canceled)

37. (Canceled)

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Original) A patient pack comprising at least one active ingredient selected from 9-[*R*-2-[[*(S)*-[[*(S)*-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) and (2*R*, 5*S*, *cis*)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1*H*)-pyrimidin-2-one (emtricitabine), and an information insert containing directions on the use of GS-7340 and emtricitabine together in combination.

42. (Original) The patient pack according to claim 41 comprising a co-formulated pill, tablet, caplet, or capsule of 100 to 1000 mg of GS-7340 and 100 to 1000 mg of emtricitabine.

43. (Original) The patient pack according to claim 41 comprising a co-formulated pill, tablet, caplet, or capsule of 300 mg of GS-7340 and 200 mg of emtricitabine.

44. (Original) The patient pack according to claim 41 comprising a separate pill, tablet, caplet, or capsule of 100 to 1000 mg of GS-7340 and 100 to 1000 mg of emtricitabine.

45. (Original) The patient pack according to claim 44 comprising a separate pill, tablet, caplet, or capsule of 150 mg of GS-7340 and 200 mg of emtricitabine.

46. (Original) A chemically stable combination of GS-7340 and emtricitabine.
47. (Original) The chemically stable combination of Claim 46 wherein the combination is a pharmaceutical dosage form.
48. (Original) The chemically stable combination of Claim 47 wherein the dosage form is oral.
49. (Currently amended) The chemically stable combination of Claims 46-48 which further comprises a third antiviral agent.
50. (Original) The chemically stable combination of Claim 49 where in the third antiviral agent is an NNRTI or PI.
51. (Original) The chemically stable combination of Claim 50 wherein the third antiviral agent is a PI.
52. (Canceled)
53. (Canceled)
54. (Original) A chemically stable oral pharmaceutical dosage form comprising GS-7340 and emtricitabine.
55. (Canceled)
56. (Canceled)
57. (Canceled)